Submission date
14/02/2006
Registration date
23/02/2006
Last edited
06/08/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Signs and Symptoms
Retrospectively registered
? Protocol not yet added
? SAP not yet added
Results added
? Raw data not yet added
Study completed

Plain English Summary

Not provided at time of registration

Study website

Contact information

Type

Scientific

Contact name

Prof Peter Goadsby

ORCID ID

Contact details

Institute of Neurology
University College London
London
WC1N 3BG
United Kingdom

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Protocol/serial number

ZINCH-1

Study information

Scientific title

Acronym

ZINCH

Study hypothesis

Zolmitriptan intranasal is more effective than placebo in the treatment of acute cluster headache.

Ethics approval(s)

Ethics approval received from the National Hospital for Neurology and Neurosurgery Ethics Committee on the 8th May 2003 (ref: 02/N031).

Study design

Randomised, placebo-controlled, double-blind cross-over trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type

Treatment

Patient information sheet

Condition

Cluster headache

Intervention

Zolmitriptan nasal spray versus placebo.

Intervention type

Drug

Pharmaceutical study type(s)

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Zolmitriptan

Primary outcome measure

Proportion of patients who have taken active drug with headache relief at 30 minutes.

Secondary outcome measures

Pain free at 30 minutes.

Overall study start date

01/09/2003

Overall study end date

01/01/2005

Reason abandoned (if study stopped)

Eligibility

Participant inclusion criteria

Cluster headache with attacks longer than 45 minutes.

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

90

Participant exclusion criteria

Contraindications to zolmitriptan in participating countries.

Recruitment start date

01/09/2003

Recruitment end date

01/01/2005

Locations

Countries of recruitment

England, Germany, Italy, United Kingdom

Study participating centre

Institute of Neurology
London
WC1N 3BG
United Kingdom

Sponsor information

Organisation

AstraZeneca (UK)

Sponsor details

Alderley Park
Macclesfield
SK10 2NA
United Kingdom

Sponsor type

Industry

Website

ROR

https://ror.org/04r9x1a08

Funders

Funder type

Industry

Funder name

AstraZeneca (UK)

Alternative name(s)

AstraZeneca PLC, Pearl Therapeutics

Funding Body Type

government organisation

Funding Body Subtype

For-profit companies (industry)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article Results 01/11/2006 Yes No

Additional files

Editorial Notes